 Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | | The end of the list has been reached or no journals were found for your choice. |
|
|
- Flu vaccination in the Philippines: challenges and interventions
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Dalmacito A. Cordero
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-11-18T06:16:56Z
DOI: 10.1177/25151355231213587
Issue No: Vol. 11 (2023)
- Designing an inclusive immunization schedule for children and adults in
India-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Farah Niazi, Karuna Nidhi Kaur, Shazina Saeed, Mohd Shannawaz
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-11-17T12:24:33Z
DOI: 10.1177/25151355231213573
Issue No: Vol. 11 (2023)
- COVID-19 vaccine immune response and plasma cell dyscrasia
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Amnuay Kleebayoon, Viroj Wiwanitkit
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-11-09T12:42:57Z
DOI: 10.1177/25151355231209733
Issue No: Vol. 11 (2023)
- Cancer vaccine strategies for the treatment of diffusely infiltrating
gliomas-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Alexander Jucht, Sydney Dumont, Channing Pooley, Luis Nicolas Gonzalez Castro
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Diffusely infiltrating gliomas – including glioblastoma (GBM), isocitrate dehydrogenase (IDH) mutant gliomas, and histone 3 (H3) altered gliomas – are primary brain tumors with an invariably fatal outcome. Despite advances in the understanding of their biology, standard, targeted and immune checkpoint inhibitor immunotherapies have proven ineffective in arresting their inexorable progression and associated morbidity and mortality. Recognizing the unique aspects of the immunogenicity of cancer cells, the last decade has seen the development and evaluation of vaccine-based therapies for the treatment of solid tumors, including gliomas. Here we review the current vaccine strategies for the treatment of GBM, IDH-mutant gliomas and diffuse midline glioma H3 K27M-altered. We discuss potential benefits and challenges of vaccine therapies in these specific patient populations.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-10-24T11:53:52Z
DOI: 10.1177/25151355231206163
Issue No: Vol. 11 (2023)
- Significant improvement of systemic lupus erythematosus manifestation in
children after autologous dendritic cell transfer: a case report and
review of literature-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Jonny, Terawan Agus Putranto, Yenny Purnama, Roedi Djatmiko, Martina Lily Yana, Enda Cindylosa Sitepu, Raoulian Irfon
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Dendritic cells (DC) are postulated to play a role in autoimmune diseases such as Systemic Lupus Erythematosus (SLE). We reported a 13-year-old female SLE patient who presents with chronic arthritis accompanied by persistent fever, dyspnea, sleep disturbance, headache, stomatitis, rash, and muscle weakness. The supporting examinations showed abnormal blood cell counts, positive antinuclear antibody profile, serositis, and neuropathy. Immunosuppressants failed to improve the condition. DC-based vaccine derived from autologous peripheral blood which was introduced with SARS-CoV-2 protein was given to this patient. There was a significant improvement in clinical and laboratory findings. Thus, DC immunotherapy appears to be a potential novel therapy for SLE that needs to be studied.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-09-13T12:32:31Z
DOI: 10.1177/25151355231186005
Issue No: Vol. 11 (2023)
- Immune checkpoints and cancer immunotherapies: insights into newly
potential receptors and ligands-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Ali N. Kamali, José M. Bautista, Michael Eisenhut, Haleh Hamedifar
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Checkpoint markers and immune checkpoint inhibitors have been increasingly identified and developed as potential immunotherapeutic targets in various human cancers. Despite valuable efforts to discover novel immune checkpoints and their ligands, the precise roles of their therapeutic functions, as well as the broad identification of their counterpart receptors, remain to be addressed. In this context, it has been suggested that various putative checkpoint receptors can be induced upon activation. In the tumor microenvironment, T cells, as crucial immune response against malignant diseases as well as other immune central effector cells, such as natural killer cells, are regulated via co-stimulatory or co-inhibitory signals from immune or tumor cells. Studies have shown that exposure of T cells to tumor antigens upregulates the expression of inhibitory checkpoint receptors, leading to T-cell dysfunction or exhaustion. Although targeting immune checkpoint regulators has shown relative clinical efficacy in some tumor types, most trials in the field of cancer immunotherapies have revealed unsatisfactory results due to de novo or adaptive resistance in cancer patients. To overcome these obstacles, combinational therapies with newly discovered inhibitory molecules or combined blockage of several checkpoints provide a rationale for further research. Moreover, precise identification of their receptors counterparts at crucial checkpoints is likely to promise effective therapies. In this review, we examine the prospects for the application of newly emerging checkpoints, such as T-cell immunoglobulin and mucin domain 3, lymphocyte activation gene-3, T-cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T-cell activation (VISTA), new B7 family proteins, and B- and T-cell lymphocyte attenuator, in association with immunotherapy of malignancies. In addition, their clinical and biological significance is discussed, including their expression in various human cancers, along with their roles in T-cell-mediated immune responses.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-08-30T08:54:23Z
DOI: 10.1177/25151355231192043
Issue No: Vol. 11 (2023)
- COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a
systematic review-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Unaiza Faizan, Lakshmi G. Nair, Maroun Bou Zerdan, Majid Jaberi-Douraki, Faiz Anwer, Shahzad Raza
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Patients with plasma cell dyscrasia are at a higher risk of developing a severe Coronavirus-2019 (COVID-19) infection. Here we present a systematic review of clinical studies focusing on the immune response to the COVID-19 vaccination in patients with plasma cell dyscrasia.Objectives:This study aims to evaluate the immune response to COVID-19 vaccines in patients with plasma cell dyscrasia and to utilize the results to improve day-to-day practice.Design:Systematic ReviewMethods:Online databases (PubMed, CINAHL, Ovid, and Cochrane) were searched following the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. Only articles published in the English language were included. Out of 59 studies, nine articles (seven prospective and two retrospective studies) were included in this systematic review. Abstracts, case reports, and case series were excluded.Results:In all nine studies (N = 1429), seroconversion post-vaccination was the primary endpoint. Patients with plasma cell disorders had a lower seroconversion rate compared to healthy vaccinated individuals and the overall percentage of seroconversion ranged between 23% and 95.5%. Among patients on active therapy, lower seroconversion rates were seen on an anti-CD38 agent, ranging from 6.5 up to 100%. In addition, a significantly lower percentage was recorded in older patients, especially in those aged equal to or greater than 65 years and those who have been treated with multiple therapies previously. Only one study reported a statistically significant better humoral response rate with the mRNA vaccine compared to ADZ1222/Ad26.Cov.S.Conclusion:Variable seropositive rates are seen in patients with plasma cell dyscrasia. Lower rates are reported in patients on active therapy, anti-CD38 therapy, and elderly patients. Hence, we propose patients with plasma cell dyscrasias should receive periodic boosters to maintain clinically significant levels of antibodies against COVID-19.Registration:PROSPERO ID: CRD42023404989Plain language summaryCOVID-19 vaccine immune response in patients with plasma cell dyscrasia- a systematic reviewBackground: Patients with plasma cell disorders are at a higher risk of developing a severe coronavirus-19 infection. Here we present a systematic review of clinical studies focusing on the immune response to the coronavirus-19 vaccination in patients with plasma cell dyscrasia.Objectives: This study aims to evaluate the immune response to COVID-19 vaccines in patients with plasma cell dyscrasia and to transcribe the results to day-to-day practice.Design: Systematic ReviewData sources: PubMed, CINAHL, Ovid, and Cochrane.Methods: Online databases were searched following the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. Only articles published in the English language were included. Abstracts, case reports, and case series were excluded. Out of 59 studies, nine articles were selected for a systematic review.Results: In all 9 studies (N = 1,429), seroconversion post-vaccination was the primary endpoint that our review assessed. Patients with plasma cell disorders had a lower seroconversion rate compared to healthy vaccinated individuals and the overall percentage of seroconversion ranged between 23 and 95.5%. Amongst patients on active therapy, lower seroconversion rates were seen in patients on an anti-CD38 agent, ranging from 6.5 up to 100%. In addition, a significantly lower percentage was recorded in older patients, especially those aged equal to or greater than 65 years and those who have been treated with multiple therapies previously. Only one study reported a statistically significant better humoral response rate with the mRNA vaccine compared to ADZ1222/Ad26.Cov.S.Conclusion: Variable seropositive rates are seen in patients with plasma cell dyscrasia. Lower rates are reported in patients on active therapy, anti-CD38 therapy, and elderly patients. Hence, we propose patients with plasma cell disorders should receive periodic boosters to maintain clinically significant levels of antibodies against COVID-19.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-08-28T06:05:24Z
DOI: 10.1177/25151355231190497
Issue No: Vol. 11 (2023)
- Active surveillance of adverse events following COVID-19 vaccines in a
tertiary care hospital-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Naveena Mary Cherian, Dravya Anna Durai, Muhammed Jaisel, Divyansh Sharma, Juny Sebastian, Chetak Kadabasal Basavaraja, Merrin Mathew
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Vaccination is a safe and effective way to prevent disease and save lives, but it may also produce some undesirable adverse events (AEs)which may affect healthy individuals. Therefore, the monitoring of AE following immunization (AEFIs) is necessary. The objective of this study was to assess the AEs following COVID-19 vaccinations in a tertiary care hospital.Methodology:The study was conducted as active vaccine safety surveillance for a period of 6 months among the COVID-19 vaccine beneficiaries of the study site. Active surveillance was conducted via initiating two telephone contacts. The first surveillance was conducted in 8 days and the second surveillance after 28 days of post-vaccination. All identified AEs following immunizations (AEFIs) were reported and analysed by the AEFI investigation team at the study site. The causality assessment of each identified AEFI was performed using the World Health Organization’s causality assessment algorithm.Results:A total of 2927 enrolled study population completed the study with a response rate of 80.85%. The study identified 902 AEFIs from 614 study populations with an incidence rate of 20.97%. Of which 794 and 79 AEFIs were associated with COVISHIELD™ and COVAXIN®, respectively. The majority of the events were reported among the age group of 18–29 years. Overall, only three events were serious and no deaths were reported among the study population. A total of 75.59% of events had a consistent causal association with vaccination and were categorized as vaccine product-related reactions. The study identified various factors such as gender (p = 0.019), age (p
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-08-26T09:57:21Z
DOI: 10.1177/25151355231193975
Issue No: Vol. 11 (2023)
- COVID-19 vaccine acceptance and its determinants among residents of Ambo
Town, West Shewa, Oromia Region, Ethiopia: cross-sectional survey-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Tamirat Bekele Beressa, Milkessa Tafa, Gudeta Duga Geresu, Amente Jorise Bacha, Diriba Alemayehu Gadisa
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Vaccines against COVID-19 are critical for preventing and managing COVID-19 because immunization is one of the most active and cost-effective health strategies for infectious disease prevention. Knowing the community’s willingness and factors affecting COVID-19 vaccine acceptance will support the design of effective promotion strategies. Therefore, this study was aimed at assessing COVID-19 vaccine acceptance and its determinants among the Ambo Town community.Method:A community-based, cross-sectional study was conducted using structured questionnaires from 1 to 28 February 2022. Four kebeles were selected randomly, and the systematic random sampling procedure was used to select the households. SPSS-25 software was used for data analysis. Ethical approval was received from the Institutional Review Committee of the College of Medicine and Health Sciences of Ambo University, and data were kept confidential.Result:Of the 391 participants, 385 (98.5%) of the respondents were not vaccinated for COVID-19, and around 126 (32.2%) of the respondents said that they would receive the vaccine if the government provided it. The multivariate logistic regression analysis revealed that males were 1.8 times more likely to accept the COVID-19 vaccine (adjusted odds ratio (AOR) = 1.8, 95% CI: 1.074–3.156) as compared to females. The acceptance of the COVID-19 vaccine was lower by 60% in those who tested for COVID-19 as compared to those who were not tested (AOR = 0.4, 95% CI: 0.27–0.69). Moreover, the participants who had chronic diseases were two times more likely to accept the vaccine. Acceptance of the vaccine was reduced by half among those who believed that there was a scarcity of data on its safety (AOR = 0.5, 95% CI: 0.26–0.80).Conclusion:The prevalence of COVID-19 vaccination acceptance was low. To enhance the acceptance of the COVID-19 vaccine, the government and different stakeholders should strengthen public education using mass media about the advantages of getting the COVID-19 vaccination.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-06-24T11:31:26Z
DOI: 10.1177/25151355231178150
Issue No: Vol. 11 (2023)
- Clinico-epidemiological profile and outcome of infected health care
workers during the three consecutive waves of COVID-19 pandemic: a
longitudinal cohort study-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Merrin Mathew, Juny Sebastian, Narayanappa Doddaiah, Anmaria Thomas, Sinchana Narayanappa
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Health care workers are considered as high-risk population, who deal with many unknown, undiagnosed, and subclinical infectious diseases in their daily life. Currently, the COVID-19 pandemic posed as an add-on burden for these frontline workers in all aspects. Although, many adverse physical and mental effects of pandemic among health care workers (HCWs) were discussed worldwide, a long-term study for delayed complications needed to be explored.Aim:The study evaluates and compares three waves of the pandemic in various aspects such as the incidence, prevalence, severity, risk factors, and variations in the pattern of COVID-19 infection, impact of vaccination, and post-infection complications among the HCWs.Methodology:A longitudinal observational study was carried out over a period of 2 years and another 6 months for follow-up. The study included all HCWs who tested positive in any one wave of COVID-19 pandemic with any one of the confirmed COVID-19 test. Each COVID-19-affected HCW was followed up through telephone calls and direct interviews conducted at the study site. Admission details and other background details of the study population were collected from the hospital records.Results:A total of 968 HCWs were COVID-19 positive in any of the three waves, and highest incidence (53.00%) was caused by the Omicron variant. High severity and hospitalization was observed in the first wave (no vaccination) and fully immunized personnel were found to be out of danger of being hospitalized during all succeeding waves (chi-square value: 87.04, p
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-06-21T11:09:02Z
DOI: 10.1177/25151355231181744
Issue No: Vol. 11 (2023)
- COVID-19 after rituximab therapy in cSLE patients
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Meghan Corrigan Nelson, Cynthia K. Manos, Elaine Flanagan, Sampath Prahalad
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who develop coronavirus disease 2019 (COVID-19). We aimed to assess the impact of prior rituximab treatment on clinical outcomes from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children with SLE. To describe the impact of rituximab on outcomes from SARS-CoV-2 infection, we conducted a retrospective study of pediatric SLE patients in our center diagnosed with COVID-19 who had previously received rituximab between February 2019 and October 2022. Patients’ clinical characteristics, disease activity, and outcomes were assessed. Of the eight subjects assessed, five required hospitalizations for COVID-19, four required ICU admission, and two were seen in the emergency department for their symptoms. One patient ultimately expired from her illness. The median time between rituximab administration and COVID-19 diagnosis was 3 months. We assessed the clinical outcomes, including the need of ICU admission and fatal outcome, of COVID-19 in our cSLE patient population after rituximab administration. Approximately 60% of our patients required hospitalization for their illness, and seven out of eight patients required healthcare utilization to include hospitalization and/or emergency department visits.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-06-21T10:30:52Z
DOI: 10.1177/25151355231181242
Issue No: Vol. 11 (2023)
- Leveraging identity and access management technology to accelerate
emergency COVID-19 vaccine delivery-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: George A. Gellert
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
COVID-19-related vaccine demand and delivery volume challenged delivery organizations as few crises have. Imperatives to ensure security of patient information, defend against cybersecurity threats, and accurately identify/authenticate clinician identity for patients remained unchanged. Deployment of identity access and management (IAM) and single sign-on (SSO) can accelerate operationalization of a vaccine delivery center when urgently needed in a crisis. Innovative application of existing IAM/SSO technology, combined with an identity governance solution, greatly accelerated vaccine delivery. Secure access enabled by IAM technology facilitated a rapid expansion (25 minutes) where 500 new vaccine delivery personnel were identified and authenticated during a period of high pandemic incidence. Existing digital identity solutions enabled a vaccine delivery organization to accelerate secure IAM of clinical staff during the peak of the COVID-19 pandemic. Existing IAM investments and capabilities that are widely implemented in nations with mature health information technology systems can greatly accelerate standing up emergent vaccine delivery capabilities and sites in the midst of a public health crisis.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-05-29T08:59:51Z
DOI: 10.1177/25151355231173830
Issue No: Vol. 11 (2023)
- Immunogenicity and safety of vaccination in children with paediatric
rheumatic diseases: a scoping review-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Jacqueline Cunninghame, Sophie Wen, Mitchell Dufficy, Amanda Ullman, Mari Takashima, Megan Cann, Rebecca Doyle
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Children with paediatric rheumatic diseases (PRDs) are at increased risk of vaccine-preventable disease. Safe and effective vaccination is central to preventive care in PRD patients; however, uncertainty surrounding immunogenicity and safety has contributed to suboptimal vaccination. The aim of this study was to evaluate treatment effect on immunogenicity to vaccination in PRD patients and assess vaccine safety, specifically adverse events following immunisation (AEFI) and disease flare. Scoping review. In this scoping review, a systematic search of PubMed, CINAHL and Embase databases was conducted from 2014 to 23 August 2022 to identify observational studies evaluating the immunogenicity and safety of commonly used vaccinations in PRD patients. The primary outcome was immunogenicity (defined as seroprotection and protective antibody concentrations), with secondary outcomes describing AEFI and disease flare also extracted. Due to extensive heterogeneity related to diagnostic and vaccination variability, narrative synthesis was used to describe the findings of each study. Study quality was assessed via the Mixed Methods Appraisal Tool. The review was prospectively registered with PROSPERO (CRD42022307212). The search yielded 19 studies evaluating immunogenicity to vaccination and incidence of AEFI and disease flares in this population, which were of acceptable quality. Corticosteroids did not have deleterious effects on vaccine response. Treatment with conventional disease-modifying antirheumatic drugs (DMARDs) and biologic DMARDs generally had no effect immunogenicity in PRD patients. While patients exhibited adequate seroprotection, protective antibody levels were lower in patients on some immunosuppressant agents. Varicella infections were recorded post vaccination in several patients with low protective antibody levels undergoing treatment with DMARDs and corticosteroids. Most vaccines appear safe and effective in PRD patients, despite immunosuppressant treatment. Booster vaccinations should be considered with some studies highlighting inadequate seroprotection following primary course of vaccinations with acceleration of antibody decline over time. There was limited evidence to support avoiding live vaccines in PRD patients.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-04-25T10:01:28Z
DOI: 10.1177/25151355231167116
Issue No: Vol. 11 (2023)
- Socioeconomic and demographic characteristics influencing the hesitancy
and refusal of COVID-19 vaccine in Ghana-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Agyemang Kwasi Sampene, Cai Li, Fredrick Oteng Agyeman, Robert Brenya
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Ghana was the first country to receive the coronavirus vaccination in West Africa from AstraZeneca or Oxford. Ghana plans to vaccinate 20 million out of the 32 million population and provide the necessary doses utilizing multilateral and bilateral agreements. As Ghana begins vaccinating its citizens, there is some skepticism about administering the coronavirus vaccine (CVV). This research aimed to analyze the socioeconomic and demographic characteristics influencing vaccine hesitancy (VH) and refusal among Ghanaians.Methods:The multinomial logistics regression model was employed to investigate the relationship between respondents’ socio-demographic characteristics and VH. The research data were gathered between March to June 2021 through an online survey.Findings:The findings of this study indicated that approximately 92.75% of the 400 respondents have heard about CVV. The study suggests that less than 5% of the participants have so far received the CVV. Most of the respondents (36.8%) indicated rejecting the CVV. Interestingly, male participants [adjusted odds ratio (AOR) = 1.048; 95% confidence interval (CI): 0.532–2.063] with higher educational backgrounds (AOR = 2.11; 95% CI: 0.870–5.121) had higher odds of being CVV hesitant or refusers. Low economic class, rural settlers, unmarried individuals, and unemployed people also had higher odds of being VH or refusers. The survey also shows that most Ghanaians refused to receive the CVV because they did not trust the system to track the vaccine’s side or adverse effects.Conclusion:Government can use social media platforms and other media platforms to effectively provide relevant information regarding the full benefit and risks of taking the virus.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-02-09T09:13:28Z
DOI: 10.1177/25151355221149336
Issue No: Vol. 11 (2023)
- Decision-making in childhood vaccination: vaccine hesitancy among
caregivers of under-5 children from a tertiary care institution in Eastern
India-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors: Soumya Swaroop Sahoo, Swayam Pragyan Parida, Arvind Kumar Singh, Sarika Palepu, Durgesh Prasad Sahoo, Vikas Bhatia
Abstract: Therapeutic Advances in Vaccines and Immunotherapy, Volume 11, Issue , January-December 2023.
Background:Acceptance of vaccines has been on a decline in recent times, with vaccine hesitancy being listed as one of the top 10 global health threats. This study analysed vaccine hesitancy and belief towards vaccination among caregivers of children aged below 5 years.Methods:In this cross-sectional study, 196 caregivers of children aged 6 months to below 5 years who had attended an immunization clinic at a tertiary care institute of Eastern India from March to May 2019 were surveyed. Consecutive sampling was used to recruit eligible study participants. The survey assessed the attitudes of parents towards childhood vaccination by using the Vaccine Hesitancy Scale and their beliefs towards vaccination. Univariate analysis was performed to assess the association of various sociodemographic factors with vaccine hesitancy.Results:Among the caregivers, most (48%) mothers were aged 26–35 years, literate and homemakers. Vaccine hesitancy was observed in 9.18% of the participants. Only the age of the child was significantly associated with vaccine hesitancy. Nearly half (48.5%) of the participants were concerned about the serious adverse effects of vaccines, and a third (30.6%) agreed that newer vaccines are associated with higher risks than the older ones. Caregivers felt that vaccines are no longer required for uncommon diseases.Conclusion:Concerns regarding vaccine hesitancy are prevalent even among caregivers attending a tertiary care institute. Thus, additional studies are required to assess hesitancy in urban, rural, remote and inaccessible areas. Policymakers ought to conduct periodic assessments and implement necessary remedial measures for the long-term sustenance of the benefits of the national immunization programme.
Citation: Therapeutic Advances in Vaccines and Immunotherapy
PubDate: 2023-02-04T05:05:29Z
DOI: 10.1177/25151355231152650
Issue No: Vol. 11 (2023)
|
Hybrid journal (It can contain Open Access articles)
